Find a Clinical Trial

PATH-2: PLS240

A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
EVALUATING THE EFFICACY AND SAFETY OF DOSE-TITRATED PLS240 IN THE
TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN INDIVIDUALS
WITH END STAGE KIDNEY DISEASE ON HEMODIALYSIS (PATH-2) WITH AN
OPEN-LABEL EXTENSION

18-80

Learn more

MLS-101-206

A PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LORUNDROSTAT ALONE, AND LORUNDOSTAT IN COMBINATION WITH DAPAGLIFLOZIN, IN ADULTS WITH HYPERTENSION AND CHRONIC KIDNEY DISEASE WITH ALBUMINURIA

18-100

Learn more

Takeda footprint

A Phase 2b, Multicenter, Randomized, Open-label, Controlled, 3-Arm Study to Evaluate the Clinical Efficacy and Safety of SHP607 in Preventing Chronic Lung Disease Through 12 Months Corrected Age Compared to Standard Neonatal Care in Extremely Premature Infants

0-1

Learn more

R3R

A Phase II, Multi-center, Open-Label Study to Assess Safety, Tolerability, Efficacy and Pharmacokinetics of R3R01 in Alport Syndrome Patients with Uncontrolled Proteinuria on ACE/ARB Inhibition and in Patients with Primary Steroid-Resistant Focal Segmental Glomerulosclerosis

12+

Learn more

BoppliTM blood pressure monitoring

A Prospective Study to Evaluate the Safety and Effectiveness of the BoppliTM in Measuring Mean Arterial Pressure (MAP), Systolic Blood Pressure (SBP), and Diastolic Blood Pressure (DBP) as Compared to an Invasive Arterial Reference

0-18

Learn more

The Connection study

A randomized, double blind, parallel-group, placebo controlled study to evaluate the efficacy and safety of IBP-9414 in premature infants 500-1500g birth weight in the prevention of necrotizing enterocolitis

No minimum age

Learn more

Assist

A Randomized, Double-blind, Placebo-controlled, Crossover Study
of Atrasentan in Subjects with IgA Nephropathy on Sodiumglucose Cotransporter-2 Inhibitors (SGLT2i)

18+

Learn more

VX19-NEN-801

A Study of the Prevalence of Apolipoprotein L1 (APOL1) Alleles Among Individuals With Proteinuric Kidney Disease Who Are of Recent African Ancestry or Geographic Origin

12-65

Learn more

AMPLITUDE

A Study to evaluate the efficacy and safety of VX-147 in Subjects with APOL1-mediated Proteinuric Kidney Disease

18-65

Learn more

A clinical trial investigating BNT113 in combination with pembrolizumab versus pembrolizumab alone for patients with a form of head and neck cancer positive for human papilloma virus 16 and expressing the protein PD-L1

An open-label Phase II randomized trial of BNT113 in combination with
pembrolizumab versus pembrolizumab monotherapy as a first line therapy in
patients with unresectable recurrent, or metastatic Head and Neck
Squamous Cell Carcinoma (HNSCC) which is positive for human papilloma
virus 16 (HPV16+) and expresses PD-L1

18+

Learn more